Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ESMO Annual Congress 2024

Read Scrip's analysis of the key news from the conference.

Read More

Featured Stories


Roche’s Plan To Muscle In On Obesity

The Swiss group’s head of cardiovascular, renal and metabolism aims to speed its incretins to market, and tackle the plateauing of weight loss and muscle wastage through combinations.

Companies Clinical Trials Metabolic Disorders

Vicore ASPIREs To Be Major IPF Player As Sanofi Jumps Onboard

The Swedish company is well positioned, and well financed with a bit of help from the French major, to push its idiopathic pulmonary fibrosis hopeful buloxibutid closer to the regulatory finishing line.

Respiratory Clinical Trials Financing

AI/ML Alliances May Give Larger Firms Another Edge, S&P Warns

All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global. Their deep pockets and early adoption are locking in a competitive advantage.

Artificial Intelligence Business Strategies Companies

Asia Spotlight

BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps?

Lilly’s Mounjaro to Pfizer’s Paxlovid, the WuXi group has been part of pharma majors’ sourcing chain. How big is the hole clients are to fill when the proposed BIOSECURE Act comes into effect? Here’s a Scrip infographic using Evaluate Pharma data.

Commercial Policy

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Executives On The Move: Two New CEOs And CFOs Each And One New CMO Among This Week's Changes

Recent changes in the industry include changes at the top at Caribou Biosciences, Prothena and 180 Life Sciences, plus Cantargia acquires chief business officer from Ultimovacs.

Leadership Executive Changes

Deal Watch: Shionogi Will Market Nxera’s Insomnia Drug In Japan

Plus deals involving Jiangsu Alphamab/CSPC, Zydus/CDRI, Junshi/JSIAMA, Repair/Genevant, Sanofi/I-Mab, Novartis/Mitem and BioAtla/Context.

Deal Watch Business Strategies

Finance Watch: More Than $4.2bn Raised Across Four New VC Funds

Private Company Edition: ARCH raised more than $3bn for its eighth fund, Frazier added $630m to its public fund that also can back crossover rounds, DCVC’s third biotech fund totaled $400m and Asabys raised €180m ($200m) for its second fund. Also, Aktis closed a $175m series B round. 

Financing Innovation

Stock Watch: When Development Goes Too Far

R&D managers can sometimes drive a drug’s development despite evidence of its unviability. This has recently resulted in a scramble to adjust in-progress trial protocol and post-approval cost-effectiveness concerns.

Stock Watch Research & Development
Interviews

Pentixapharm Poised To Make A Splash In The Radiopharmaceuticals Pool

The German group is spinning off from Eckert & Ziegler and listing in Frankfurt, though a leap to the NASDAQ will likely follow once it has more data on a lymphoma theranostic.

Financing Business Strategies

AstraZeneca's Different Thinking On Weight Management Behind Eccogene Deal

Sharon Barr, AstraZeneca’s executive vice president, biopharmaceuticals R&D, in an interview with Scrip, outlines how the company is using a holistic approach to define a new competitive landscape in the weight loss sector. She also sees new frontiers for the firm and its potential partners both in China and beyond to jointly explore aimed at maintaining healthy muscle mass while decreasing body fat.

China Research & Development

BioCentriq CEO On Next Phase Of Growth With GC Support

In a video interview with Scrip, Syed Husain, CEO of the US-based cell therapy CDMO BioCentriq, talks about the company’s role in parent GC’s growth strategy and business priorities, the cell and gene therapy manufacturing market and his views on the US BIOSECURE Act.

South Korea United States

Early Data In Hand, Vesper Bio Takes On GSK And Alector

Emerging Company Profile: Danish group Vesper Bio is advancing an oral sortilin inhibitor in frontotemporal dementia, and is aiming to get to market in a similar timeframe to its much larger rivals.

Emerging Company Profile Business Strategies
See All
Graphics

BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps?

Lilly’s Mounjaro to Pfizer’s Paxlovid, the WuXi group has been part of pharma majors’ sourcing chain. How big is the hole clients are to fill when the proposed BIOSECURE Act comes into effect? Here’s a Scrip infographic using Evaluate Pharma data.

Commercial Policy

Progress Or Hype? A Decade Of Cell Therapy In Japan

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Japan Policy

Obesity Rules Large-Cap Stocks In First Half Of 2024

Lilly and Novo Nordisk were top performers among large-cap pharma stocks, while the stock prices of Bristol Myers and Gilead declined the most.

Business Strategies Companies

The IPO Queue Fills Up, But A Recovery Is A Way Off

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

Financing Commercial
See All
Recent Stories

Gilead Seals VLs For Lenacapavir Amid Concerns Around Price, API Supplies

Gilead strikes voluntary licensing agreements with six generic manufacturers for lenacapavir but health groups seek clarity on pricing and seeming API supply restrictions. All eyes are also on the patent opposition case in India.

Commercial Business Strategies

Eight Recent Deals Tapping AI/ML For R&D

Big pharmas, biotechs and the US government look to partner with artificial intelligence and machine learning firms for discovery efforts across therapeutic areas and modalities.

Deals Artificial Intelligence

With FDA Hold Lifted, Avidity Works To Bring First DM1 Therapy To Market

Avidity hopes to complete enrollment in mid-2025 for an ongoing Phase III trial of its antibody-oligonucleotide conjugate in myotonic dystrophy type 1, which has no approved drug therapy.

Clinical Trials Rare Diseases

Executives On The Move: Two New CEOs And CFOs Each And One New CMO Among This Week's Changes

Recent changes in the industry include changes at the top at Caribou Biosciences, Prothena and 180 Life Sciences, plus Cantargia acquires chief business officer from Ultimovacs.

Leadership Executive Changes

Deal Watch: Shionogi Will Market Nxera’s Insomnia Drug In Japan

Plus deals involving Jiangsu Alphamab/CSPC, Zydus/CDRI, Junshi/JSIAMA, Repair/Genevant, Sanofi/I-Mab, Novartis/Mitem and BioAtla/Context.

Deal Watch Business Strategies

Lilly Makes Another Big Investment In Manufacturing Capacity

The drug maker will spend $4.5bn on a “Lilly Medicine Foundry” that it said would provide extra manufacturing capacity as well as research ways to improve manufacturing processes.

Manufacturing Business Strategies

Finance Watch: More Than $4.2bn Raised Across Four New VC Funds

Private Company Edition: ARCH raised more than $3bn for its eighth fund, Frazier added $630m to its public fund that also can back crossover rounds, DCVC’s third biotech fund totaled $400m and Asabys raised €180m ($200m) for its second fund. Also, Aktis closed a $175m series B round. 

Financing Innovation

Granite Weighs Gritstone Down

The vaccine maker might be facing the end of the road following another feeble readout from its mid-stage colorectal cancer study.

Clinical Trials Cancer

FDA Backs Oryzon’s Phase III Plans For Borderline Personality Disorder Drug

Would-be partners for the Spanish firm’s vafidemstat will be closely following the news that regulators in the US are looking favorably on the LSD1 inhibitor’s potential as a therapy for the debilitating psychiatric illness.

Neurology Clinical Trials

Santen Fortifies Glaucoma Strategy With Sepetaprost Japan Filing

The dual agonist of the FP and EP3 receptors has shown efficacy in a Japanese Phase III trial and completed its US Phase II study, which aligns with the Japanese firm’s global expansion strategy for glaucoma products.

Japan Ophthalmic

Kailera’s $400m Series A Round Funds Ambitious Obesity Plans

A new contender emerges in obesity with pipeline assets from Jiangsu Hengrui, including a Phase III dual agonist, and an experienced team already focused on commercial hurdles.

Business Strategies Financing

Shattuck Shifts Gears After Lackluster CD47-Targeting Bispecific Results

The biotech is cutting jobs and discontinuing development of its anti-CD47 bispecific for blood cancers and moving its focus to SL-325, which targets the TL1A-DR3 axis in autoimmune diseases.

Clinical Trials ImmunoOncology
UsernamePublicRestriction

Register